Bio Pharma Dive

DECEMBER 4, 2024

Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program and Takeda acquired a blood disease therapy.

Licensing 147

Licensing Licensing Drugs Protein 147

Pharmaceutical Technology

APRIL 13, 2023

Dyadic International has announced expansion of a licence agreement for its C1-cell protein expression platform with South African consortium Rubic One Health. The expanded licence will include the development of vaccines and therapeutic proteins beyond Covid-19 for human and animal health markets in Africa.

Production 279

Production Vaccination Vaccine Protein 279

Pharma Mirror

OCTOBER 1, 2022

HK), an innovation and R&D-driven pharmaceutical company; today announced that they have entered into an exclusive licensing agreement for Simcere’s IL-2 mutant fusion protein (IL-2 mu-Fc) autoimmune drug candidate, SIM0278. Simcere will retain all rights to develop and commercialise SIM0278 within Greater China.

Licensing 130

Licensing Licensing Protein Development 130

Pharmaceutical Technology

OCTOBER 7, 2024

mRNA-based vaccines, which instruct cells to produce proteins that can prevent or treat disease, show great promise in precision medicine.

Licensing 130

Licensing Licensing Protein Vaccination 130

Bio Pharma Dive

MAY 12, 2022

The pharma will pay $90 million to license BridgeBio's experimental candidate, joining a lengthening list of large drugmakers aiming to treat cancer by blocking a protein called SHP2.

Licensing 173

Licensing Licensing Protein Drugs 173

Pharmaceutical Technology

APRIL 25, 2023

German biotechnology firm 3B Pharmaceuticals (3BP) has entered into a licensing agreement with Novartis Innovative Therapies for its fibroblast activation protein (FAP)-targeting peptide technology. 3BP receives an initial payment of $40m, and $425m as development, regulatory and commercial milestone payments.

Licensing 130

Licensing Licensing Clinical Development Clinical Trials 130

pharmaphorum

JANUARY 12, 2021

ImmunityBio has licensed technology underpinning a COVID-19 vaccine that could be administered orally rather than by injection from UK biotech iosBio. ImmunityBio’s vaccine design drives both antibody and T-cells to the spike (S) protein and nucleocapsid (N) protein.

Licensing 119

Licensing Licensing Vaccination Vaccine 119

BioSpace

APRIL 16, 2024

As its lead oral targeted protein degrader moves through Phase III in partnership with Pfizer, Arvinas signs a licensing deal handing over all rights and responsibilities to Novartis.

Protein 86

Protein Licensing Licensing 86

pharmaphorum

NOVEMBER 23, 2021

Sanofi has bolstered its push into mRNA-based therapies with a new licensing deal – but not as might be expected with some up-and-coming biotech company. The post Chinese tech giant Baidu licenses mRNA algorithm to Sanofi appeared first on. Specific financial terms have not been disclosed.

Licensing 105

Licensing Licensing Vaccine Vaccination 105

BioSpace

SEPTEMBER 16, 2020

Recently licensed from Planet Biotechnology, the candidate is a recombinant protein made from human angiotensin converting enzyme 2 (ACE2) fused to a human immunoglobulin G Fc fragment.

Licensing 142

Licensing Licensing Protein 142

pharmaphorum

NOVEMBER 15, 2022

Their earlier partnership , signed in 2020, covered small molecule drugs directed at SLC transporters, a class of more than 450 human membrane proteins that are gatekeepers for controlling the movement of metabolites in and out of cells and organs. The post Roche deepens ties with Jnana with a second licensing deal appeared first on.

Licensing 105

Licensing Licensing Protein Genetics 105

Pharmaceutical Technology

APRIL 21, 2023

Astellas will license a suite of single-domain antibody (VHH) libraries from Twist for five years to conduct research and development activities. This will create high-quality VHH libraries for use against any target protein. The VHH antibodies’ small size allows them to access difficult-to-access targets with tight binding affinity.

Antibody 264

Antibody Licensing Licensing Protein 264

Pharmaceutical Technology

OCTOBER 21, 2022

DJS focuses on the discovery and development of antibody therapies that act on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs). AbbVie has announced the acquisition of UK-based biotechnology firm DJS Antibodies for nearly $255m in cash at closing.

Antibody 217

Antibody Protein Licensing Licensing 217

Pharmaceutical Technology

JULY 29, 2022

The Food and Drug Administration (FDA) has acc epted to review ImmunityBio’s Biologics License Application (BLA) for N-803 to treat Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients with or without Ta or T1 disease.

Trials 264

Trials Clinical Trials Clinical Trials Licensing 264

pharmaphorum

AUGUST 25, 2021

Eli Lilly has bolstered its position the fast-emerging area of protein degrader drugs, agreeing a $1.6 Lilly has bought into Lycia’s lysosomal targeting chimera (LYTAC) protein degradation technology, developed by Bertozzi at Stanford University, with an initial focus on projects in immunological disease and pain.

Protein 69

Protein Licensing Licensing Drugs 69

XTalks

JUNE 20, 2022

Alnylam’s Onpattro was its first licensed and approved RNAi therapy for ATTR polyneuropathy. Hereditary ATTR has an autosomal dominant pattern of inheritance and is caused by point mutations in the transthyretin ( TTR ) gene that codes for the transthyretin transport protein found in the plasma and cerebrospinal fluid.

FDA Approval 98

FDA Approval Protein Genetics RNA 98

pharmaphorum

SEPTEMBER 2, 2020

Vopratelimab is a monoclonal antibody that binds to and activates the Inducible T Cell CO-Stimulator (ICOS), a protein on the surface of certain T cells that is believed to stimulate an immune response against a patient’s cancer. The post Gilead licenses Jounce immunotherapy for $800m appeared first on. In 2016 Celgene signed a $2.6

Licensing 71

Licensing Licensing Antibody Immune Response 71

BioSpace

DECEMBER 18, 2023

Israel-based cancer immunotherapy company Compugen will receive $60 million upfront from Gilead for the license to its antibody, which blocks the interaction between the IL-18 binding protein and IL-18.

Licensing 102

Licensing Licensing Protein Antibody 102

BioSpace

NOVEMBER 7, 2022

Sanofi inked a research collaboration and license agreement with Stockholm, Sweden-based Salipro Biotech to develop therapeutic antibodies or small molecules that target membrane proteins.

Protein 59

Protein Licensing Licensing Antibody 59

Pharmaceutical Technology

JUNE 21, 2023

Hemgenix works by dosing a patient with an engineered adeno-associated virus (AAV), containing the gene responsible for producing a protein called factor IX. This protein helps to form blood clots and stop bleeding, with haemophilia B arising when the body is partially or completely unable to produce it.

Gene Therapy 246

Gene Therapy Gene Protein Sales 246

BioPharma Reporter

MARCH 27, 2023

The biotech is launched with an antibody-based protein degradation platform, with technology licensed from UCSF.

Protein 52

Protein Licensing Licensing Antibody 52

BioPharma Reporter

MARCH 27, 2023

The biotech is launched with an antibody-based protein degradation platform, with technology licensed from UCSF.

Protein 52

Protein Licensing Licensing Antibody 52

BioPharma Reporter

APRIL 18, 2023

Dyadic extends its licensing agreement with Rubic for the use of its C1-cell protein expression platform.

Licensing 52

Licensing Licensing Protein Vaccination 52

The Pharma Data

MARCH 30, 2021

Basel, March 30, 2021 — Novartis has obtained exclusive worldwide rights to develop and commercialize therapeutic applications for a library of Fibroblast Activation Protein (FAP) targeting agents including FAPI-46 and FAPI-74, through an assignment agreement with iTheranostics, Inc., an affiliate of SOFIE Biosciences, Inc.

Protein 52

Protein Licensing Licensing Containment 52

Pharmaceutical Technology

JULY 1, 2022

Twist's VHH libraries, used for discovering and developing antibodies for use in immuno-oncology, will be licensed by Ildong for three years for research and development works. . This VHH library licensing agreement with Ildong is our first collaboration with a South Korea-based company and broadens our presence in the Asia-Pacific region.”.

Antibody 147

Antibody Development Licensing Licensing 147

Pharmaceutical Technology

AUGUST 2, 2022

Sosei Heptares , a corporate brand of Sosei Group Corporation, has signed a new drug discovery partnership and option-to-license agreement with AbbVie for discovering, developing and marketing new therapies for neurological ailments. On signing of the deal, AbbVie will make an upfront payment of $40m to Sosei Heptares.

Development 147

Development Licensing Licensing Branding 147

Pharmaceutical Technology

JANUARY 19, 2023

Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain. SK bioscience is manufacturing Nuvaxovid’s drug substance, and drug product for domestic use after the companies signed a licensing agreement in Korea.

Vaccination 147

Vaccination Vaccine Immune Response Protein 147

Pharmaceutical Technology

SEPTEMBER 22, 2022

AVR-RD-04 works by genetically modify a patient's hematopoietic stem cells (HSCs) to express the gene that encodes the cystinosin protein. Cystinosis patients have a high deficiency of this protein. A rare and fatal ailment, cystinosis is characterised by cystine buildup in cellular organelles called lysosomes.

Gene Therapy 147

Gene Therapy Gene Protein Clinical Trials 147

Pharmaceutical Technology

DECEMBER 6, 2022

According to the agreement, ExpreS 2 ion will hold the exclusive right for licensing the CMV vaccine candidate under a possible development and commercialisation agreement. Until 2025, the companies will equally share the research and intellectual property licensing expenses under the partnership.

Vaccination 130

Vaccination Vaccine Development Immune Response 130

pharmaphorum

FEBRUARY 11, 2021

ACI-35.030, partnered with Johnson & Johnson, is designed to stimulate the body to generate antibodies against tau protein, one of the factors though to play a role in the development of AD dementia. In AD, the protein goes haywire, forming tangles that have been linked to cell damage and neuronal death.

Antibody 128

Antibody Protein Vaccination Vaccine 128

Pharmaceutical Technology

NOVEMBER 1, 2022

An oral inhibitor of exportin 1 (XPO1), Nexpovio works by selectively attaching to hindering the nuclear export protein XPO1. It prevents the tumour suppressor, growth regulatory and anti-inflammatory proteins’ nuclear export, causing their build-up in the nucleus and boosting their anti-cancer activity in the cell.

Protein 130

Protein FDA Approval Production Licensing 130

pharmaphorum

MAY 12, 2022

Bristol-Myers Squibb’s Celgene unit has clearly been impressed by progress in its four-year-old alliance with Evotec on protein degradation. These small drug compounds destabilise proteins by bringing them into proximity with enzymes called E3 ubiquitin ligases that cause them to be broken down. billion partnership last week.

Protein 52

Protein Genomics Genome Drugs 52

pharmaphorum

FEBRUARY 24, 2022

Viral or bacterial infections, or airway irritants can damage lung cells, causing them to release damage associated molecular pattern (DAMP) molecules that attach to and activate the receptor for advanced glycation endproducts (RAGE) protein found on a cell’s membrane.

Licensing 64

Licensing Licensing Development Drugs 64

Pharmaceutical Technology

JANUARY 23, 2023

Another key player in the LN market is Aurinia Pharmaceuticals’s Lupkynis, having gained market approval in the US in 2021 and in the EU (licensed to Otsuka Pharmaceutical Co ) in 2022.

Marketing 278

Marketing Production Drugs Trials 278

Pharmaceutical Technology

APRIL 26, 2023

MiNA Therapeutics has entered into a research collaboration and option licensing agreement with BioMarin Pharmaceutical to speed up the development of therapeutic ribonucleic acid activation (RNAa) candidates to treat rare genetic diseases. The option licensing agreement is based on early-stage clinical results.

Development 130

Development Genetic Disease Genetics Gene Therapy 130

Pharmaceutical Technology

MAY 19, 2023

ImmunoForge and Duke University plan to revolutionise the delivery of peptide and protein drugs. They will continue to create open innovation and joint research opportunities with domestic and foreign companies, universities and research institutes for the ELP technology and ImmunoForge’s new drug pipeline.”

Development 130

Development Drugs Licensing Licensing 130

pharmaphorum

JULY 8, 2022

Swedish rare disease specialist Sobi is paying $55 million upfront to license rights to ADC Therapeutics’ lymphoma therapy Zynlonta – approved in the US last year – in Europe and other international markets. The post Sobi bolsters blood division via $435m ADC licensing deal appeared first on.

Licensing 52

Licensing Licensing Sales Marketing 52